First, the treatment with PD-1 inhibitors enhanced the capacity of CD8+ TRM cells in melanoma, lung cancer, and esophageal cancer (Edwards et al., 2018; Han et al., 2020; Abdeljaoued et al., 2022). Here, CD8A is linked to melanoma.